A5084550163- Growth Hormone and Insulin-like Growth Factors
- Birth, Development, and Health
- Diet and metabolism studies
- Pituitary Gland Disorders and Treatments
- Metabolism and Genetic Disorders
- Lipid metabolism and disorders
- Digestive system and related health
- Obesity, Physical Activity, Diet
- Genetic Syndromes and Imprinting
- Metabolism, Diabetes, and Cancer
- Ophthalmology and Eye Disorders
- Cancer Risks and Factors
- Genetic factors in colorectal cancer
- Sexual Differentiation and Disorders
- Hypothalamic control of reproductive hormones
- Meningioma and schwannoma management
- Intestinal Malrotation and Obstruction Disorders
Karolinska Institutet
2017-2024
Karolinska University Hospital
2019-2024
Growth hormone (GH) is prescribed for an increasing range of indications, but there has been concern that it might raise cancer risk. Published data are limited. To examine risks in relation to GH treatment. Cohort study. Population-based. 23,984 patients treated with recombinant human (r-hGH) eight European countries since this treatment was first used 1984. Cancer expectations from country-specific national population statistics. incidence and mortality. Incidence mortality the cohort were...
A secular trend for earlier menarcheal age has been established in girls but there are few studies of pubertal timing boys.To determine if is a among boys.For this population-based retrospective cohort study conducted Gothenburg, Sweden, we collected heights and weights from school health records boys born consecutively January 1 onwards 1947 every 5 years 1951 to 1996 (n = 375 each birth 1947-1991, n 340 the 1996, 4090 total cohort). We estimated at peak height velocity (PHV), maximum...
Concerns about the cardiovascular safety of recombinant human growth hormone (rhGH) treatment in childhood have recently been raised; however, long-term studies are limited.To investigate risk overall and severe events patients previously treated with rhGH whether there is an association duration or dose.This nationwide population-based cohort study included during from January 1, 1985, to December 31, 2010, Sweden, follow-up through 2014. Included were owing isolated deficiency (GHD), small...
Background Increased risk of neoplastic events after recombinant human growth hormone (rhGH) treatment in childhood has been an ongoing concern but long-term safety data are limited. Methods A nationwide population-based cohort study Sweden patients treated with rhGH during between 1985-2010, due to isolated deficiency (GHD), small for gestational age (SGA) and idiopathic short stature (ISS). The comparison group consisted 15 age-, sex-, region-matched controls per patient, randomly selected...
Abstract Context There has been concern that GH treatment of children might increase meningioma risk. Results published studies have inconsistent and limited. Objective To examine risks in relation to treatment. Design Cohort study with follow-up via cancer registries other registers. Setting Population-based. Patients A cohort 10,403 patients treated childhood recombinant five European countries since this was first used 1984. Expected rates from national registration statistics. Main...
<b><i>Introduction:</i></b> Growth hormone (GH) is a central for regulating linear growth during childhood and also highly involved in the metabolism of lipids, carbohydrates, protein. However, few studies report on how treatment with GH influences metabolic parameters. Our aim was to investigate effects different doses short children peak levels low normal range. <b><i>Design:</i></b> Thirty-five prepubertal (&#x3c;−2.5 SDS), aged 7–10...
SAGhE is a large independent European consortium including eight different countries (Belgium, France, Germany, Italy, The Netherlands, Sweden, Switzerland, and the UK) which was set up to evaluate long-term safety of rhGH in cohort (>24 000) young adult patients treated during childhood (1). In this report, overall cause-specific mortality assessed by comparison general population data calculate standardized ratios (SMR). Patients were subdivided into risk groups: 1) low-risk, further group...
This nationwide population-based study assessed the long-term risk of cardiovascular events in patients who had received rhGH therapy during childhood and adolescence. The cohort comprised 3.408 subjects treated under GHD, SGA or ISS indications, 50 036 age-, sex-, region-based matched controls. Median follow-up was 14.9 years (to age 25 years) with a total 795 125 person-years. Patients each diagnostic group significant higher for than controls (hazard ratio 1.69; 95% CI, 1.302.19),...